Satellos Bioscience Inc. (MSLE)
Satellos Bioscience Inc. (MSLE) Stock Price, Analysis & Data
| Bid | 10.2 |
| Market Cap | 208.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -34.61M |
| Beta | n/a |
| EPS (ttm) | -1.94 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.49 |
| P/B (ttm) | 2.89 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 10.15 |
| Volume | 4,459 |
| Avg. Volume (20D) | 55,330 |
| Open | 9.95 |
| Previous Close | 9.94 |
| Day's Range | 9.79 - 9.95 |
| 52-Week Range | 4.91 - 13.39 |
| Analyst | Strong Buy |
| Price Target | 23 (134.45%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MSLE
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenn...
Financial Performance
In 2025, Satellos Bioscience's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -24.87M, an increase of 20.54%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for MSLE stock is "Strong Buy". The 12-month stock price forecast is 23, which is upside of 134.45% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
